Practical implication
MAHs and SMEs must review the updated fee structures and assess the potential for fee reductions on safety-related submissions to align with the new regulatory framework.
The guidance document on fees payable to the European Medicines Agency was updated to reflect the application of the New Fee Regulation (Regulation (EU) 2024/568). This includes details about fee calculations, payment modalities, and reductions applicable to safety-related submissions, essential for mandatory pharmacovigilance activities like Periodic Safety Update Reports and Post-Authorisation Safety Study protocols.
What changed: The application of fee calculations and payment modalities under the New Fee Regulation (Regulation (EU) 2024/568) has been clarified, including new reduction criteria for SMEs and public health products.
Why it matters: This update ensures that marketing authorization holders (MAHs) and small and medium-sized enterprises (SMEs) have a clear understanding of the fee structures, facilitating better financial planning for mandatory pharmacovigilance activities.
Practical implication: MAHs and SMEs must review the updated fee structures and assess the potential for fee reductions on safety-related submissions to align with the new regulatory framework.
View original source
Published from the Firecrawl policy change extraction pipeline.
